IICP is a registered charitable society working in the disability sector since 1974
EBITDA for the period rose by 23.2% to Rs. 3,797 million
CRL shall invest another Rs. 200 crore for creation of additional beds
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
She has held senior positions at Coca-Cola in China and PepsiCo in India
The CDMO upgrade represents a transformational step for Remedium Lifecare
Standalone profit from operations for the quarter were Rs. 162 crores
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Subscribe To Our Newsletter & Stay Updated